{
    "pmcid": "11324185",
    "qa_pairs": {
        "How do many S2-specific monoclonal antibodies contribute to viral clearance despite being non-neutralizing?": [
            "They mediate antibody-dependent cellular cytotoxicity (ADCC).",
            "They inhibit viral replication directly.",
            "They block the receptor binding domain (RBD).",
            "They prevent viral entry into host cells."
        ],
        "What functional role does the S2 subunit play in the SARS-CoV-2 spike protein?": [
            "Facilitates membrane fusion.",
            "Contains the receptor binding domain.",
            "Initiates viral replication.",
            "Mediates viral assembly."
        ],
        "What is the primary reason the S2 subunit of the SARS-CoV-2 spike protein is considered a promising target for broad-spectrum antibodies?": [
            "The S2 subunit is more conserved across variants and related coronaviruses.",
            "The S2 subunit contains the receptor binding domain (RBD), which is crucial for viral entry.",
            "The S2 subunit is highly variable, allowing for diverse antibody responses.",
            "The S2 subunit is responsible for the initial attachment of the virus to host cells."
        ],
        "What potential advantage do nanobodies have when targeting the S2 subunit of the spike protein?": [
            "Their small size and stability allow them to target conserved regions effectively.",
            "They can easily mutate to adapt to new viral variants.",
            "They are less expensive to produce than traditional antibodies.",
            "They can target the receptor binding domain more efficiently."
        ],
        "Which specific monoclonal antibody demonstrated broad neutralization across SARS-CoV-2 variants and other coronaviruses?": [
            "C20.119",
            "B12.34",
            "D45.67",
            "E78.90"
        ]
    }
}